Immunome posts FY2023 net loss of $106.8M; cash $138.1M, AL102 Phase 3 data due Q1 2025

Immunome Inc.

Net loss $106.8M ($5.38 per share) for FY2023; cash and equivalents $138.1M as of Dec 31, 2023 (prior to Feb 2024 $230M offering).
AL102 Phase 3 RINGSIDE topline data expected Q1 2025; IND filings for IM-1021 and IM-3050 expected Q1 2025.
Closed acquisition of AL102 from Ayala (Mar 2024) and licensed IM-1021 from Zentalis (Jan 2024).
Completed $230M underwritten offering in Feb 2024, extending cash runway into 2026.
R&D expenses $23.1M, IPR&D $80.8M, G&A $19.7M for FY2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Immunome Inc. reported the full-year ended December 31, 2023 results: net income $106.8 million, EPS $5.38.

Period: the full-year ended December 31, 2023
Net income: $106.8 million
EPS: $5.38
Result: reported results

Exact text from the filing

Immunome reported a net loss of $106.8 million, or basic and diluted net loss per share attributable to common stockholders of $5.38, for the year ended December 31, 2023.

View on SEC.gov

326 earnings releases filed in the last 30 days. Browse all earnings releases →

Immunome Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-040503

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.